Multiple small studies have demonstrated the clinical benefit of progestins, but variable response rates have been documented depending on the route of administration (IM versus oral), tumor grade, histology, PR expression status, and the line of therapy (i.e., first or subsequent exposure to endocrine therapy) [34]. This evidence concerns the gene PGR and neoplasm.